{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:11:49Z","timestamp":1793272309188,"version":"4.5.0"},"reference-count":192,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["806975"],"award-info":[{"award-number":["806975"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ard.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T23:27:56Z","timestamp":1750116476000},"page":"1068-1089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Primary Sj\u00f6gren\u2019s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sj\u00f6gren\u2019s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9948","authenticated-orcid":false,"given":"Simon J.","family":"Bowman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-4679","authenticated-orcid":false,"given":"Raphael","family":"Porcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-7640","authenticated-orcid":false,"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liseth","family":"de Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenny","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Jousse-Joulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-0344","authenticated-orcid":false,"given":"Elena","family":"Pontarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-5865","authenticated-orcid":false,"given":"Jessica","family":"Marvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpendra","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-549X","authenticated-orcid":false,"given":"Benjamin A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Nayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-9614","authenticated-orcid":false,"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggy","family":"Pincemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Bouillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-597X","authenticated-orcid":false,"given":"Katherine M.","family":"Hammitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-7245","authenticated-orcid":false,"given":"Marie","family":"Wahren-Herlenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5571-2324","authenticated-orcid":false,"given":"Joel","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-0733","authenticated-orcid":false,"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Laigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-9983","authenticated-orcid":false,"given":"Philippe","family":"Moingeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"Sreih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-0141","authenticated-orcid":false,"given":"Andre","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-9709","authenticated-orcid":false,"given":"Wen-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Wisniacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Piatrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0001","first-page":"97","article-title":"Primary Sj\u00f6gren\u2019s Syndrome","volume":"379","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1136\/annrheumdis-2014-206860","article-title":"Is primary Sj\u00f6gren\u2019s syndrome an orphan disease? A critical appraisal of prevalence studies in Europe","volume":"74","author":"Cornec","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003591","article-title":"Estimated prevalence, incidence and healthcare costs of Sj\u00f6gren\u2019s syndrome in France: a national claims-based study","volume":"10","author":"Seror","year":"2024","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sj\u00f6gren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sj\u00f6gren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0006","series-title":"Autoimmunity: from bench to bedside [Internet]","article-title":"Sj\u00f6gren\u2019s syndrome","author":"Sarmiento-Monroy","year":"2013"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/rheumatology\/keh170","article-title":"Measurement of fatigue and discomfort in primary Sj\u00f6gren\u2019s syndrome using a new questionnaire tool","volume":"43","author":"Bowman","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sj\u00f6gren's Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sj\u00f6gren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/art.42789","article-title":"Association of combined anti-Ro52\/TRIM21 and anti-Ro60\/SSA Antibodies with increased Sj\u00f6gren disease severity through interferon pathway activation","volume":"76","author":"Bettacchioli","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/rheumatology\/keab939","article-title":"Clinical picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren's syndrome: results from a harmonized dataset (1981-2021)","volume":"61","author":"Chatzis","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s10875-011-9553-3","article-title":"Active immunological profile is associated with systemic Sj\u00f6gren\u2019s syndrome","volume":"31","author":"Martel","year":"2011","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","article-title":"Mortality and causes of death in primary Sj\u00f6gren\u2019s syndrome: a prospective cohort study","volume":"50","author":"Theander","year":"2004","journal-title":"Arthritis Rheumat"},{"issue":"5 Suppl 51","key":"10.1016\/j.ard.2025.05.004_bib0017","first-page":"S66","article-title":"Mortality in Sj\u00f6gren\u2019s syndrome","volume":"26","author":"Voulgarelis","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0018","first-page":"450","article-title":"Rate, risk factors and causes of mortality in patients with Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis of cohort studies","volume":"55","author":"Singh","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sj\u00f6gren\u2019s syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239769","article-title":"Akpek EK. Extraglandular ocular involvement and morbidity and mortality in primary Sj\u00f6gren\u2019s Syndrome","volume":"15","author":"Mathews","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.3390\/ijms22063090","article-title":"Role of the innate immunity signaling pathway in the pathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"22","author":"Shimizu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0022","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/rheumatology\/key360","article-title":"Wahren-Herlenius M. Innate immunity and interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Bodewes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0023","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren\u2019s syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0024","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sj\u00f6gren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sj\u00f6gren\u2019s related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ard.2025.05.004_bib0026","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fimmu.2013.00142","article-title":"The interferon-signature of Sj\u00f6gren\u2019s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases","volume":"4","author":"Nguyen","year":"2013","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0027","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren's syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13145","article-title":"Disease mechanisms in Sj\u00f6gren\u2019s syndrome: what do we know?","volume":"95","author":"Jonsson","year":"2022","journal-title":"Scand J Immunol"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0029","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","article-title":"Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren's syndrome","volume":"48","author":"Salomonsson","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"27","key":"10.1016\/j.ard.2025.05.004_bib0030","doi-asserted-by":"crossref","first-page":"13490","DOI":"10.1073\/pnas.1905301116","article-title":"Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology","volume":"116","author":"Nayar","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0031","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42003-022-03344-6","article-title":"Immunofibroblasts regulate LT\u03b13 expression in tertiary lymphoid structures in a pathway dependent on ICOS\/ICOSL interaction","volume":"5","author":"Nayar","year":"2022","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0032","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41467-024-54686-0","article-title":"Molecular and spatial analysis of tertiary lymphoid structures in Sj\u00f6gren\u2019s syndrome","volume":"16","author":"Nayar","year":"2025","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0033","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9","article-title":"Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL-13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj\u00f6gren\u2019s dyndrome","volume":"44","author":"Amft","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0034","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/art.21062","article-title":"Association of CXCL-13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sj\u00f6gren\u2019s syndrome","volume":"52","author":"Barone","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/rheumatology\/kez255","article-title":"CXCL-13 as biomarker for histological involvement in Sj\u00f6gren\u2019s syndrome","volume":"59","author":"Colafrancesco","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.004_bib0036","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2017.10.019","article-title":"Cytokines as therapeutic targets in primary Sj\u00f6gren syndrome","volume":"184","author":"Retamozo","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0037","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar3504","article-title":"Impact of interleukin-21 in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands","volume":"13","author":"Kang","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.ard.2025.05.004_bib0038","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/annrheumdis-2020-217646","article-title":"Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sj\u00f6gren\u2019s syndrome with ectopic germinal centres and MALT lymphoma","volume":"79","author":"Pontarini","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"35","key":"10.1016\/j.ard.2025.05.004_bib0039","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1073\/pnas.1503315112","article-title":"IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs","volume":"112","author":"Barone","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.ard.2025.05.004_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaut.2017.11.003","article-title":"Th17 cells in primary Sj\u00f6gren's syndrome: pathogenicity and plasticity","volume":"87","author":"Verstappen","year":"2018","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0041","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.2792","article-title":"Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj\u00f6gren\u2019s syndrome","volume":"45","author":"Lessard","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0042","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1038\/s41467-022-30773-y","article-title":"Genome-wide association study identifies Sj\u00f6gren's risk loci with functional implications in immune and glandular cells","volume":"13","author":"Khatri","year":"2022","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.05.004_bib0043","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/annrheumdis-2023-eular.1719","article-title":"POS0112 Deucravacitinib reduces interferons, B-cell pathways and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 Paisley study [abstract]","volume":"82","author":"Kahlenberg","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"10.1016\/j.ard.2025.05.004_bib0044","first-page":"0620","article-title":"Clinical efficacy and patient-reported outcomes in anti-Ro\/Sj\u00f6gren\u2019s syndrome-related antigen A antibody-positive patients with active SLE treated with deucravacitinib in the phase 2 PAISLEY Trial [abstract]","volume":"76","author":"Fisher","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0046","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren\u2019s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0048","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.revmed.2023.07.001","article-title":"French national diagnostic and care protocol for Sj\u00f6gren's disease","volume":"44","author":"Devauchelle-Pensec","year":"2023","journal-title":"Rev Med Interne"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0049","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren\u2019s syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren Syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0051","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0052","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0053","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-017-1475-x","article-title":"Comparison of 2002 AECG and 2016 ACR\/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sj\u00f6gren's syndrome","volume":"19","author":"Le Goff","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0054","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0055","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0056","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren\u2019s syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0057","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.42772","volume":"76","author":"Pontarini","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0058","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome: results from a phase ii randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0059","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0061","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren's syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0062","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0063","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0064","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0065","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-002979","article-title":"Leflunomide\/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sj\u00f6gren\u2019s syndrome that show potential to predict and monitor clinical response","volume":"9","author":"Hamkour","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0067","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren's syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"10320","key":"10.1016\/j.ard.2025.05.004_bib0068","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous Ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome, a randomized double blind placebo-controlled phase 2 dose finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ard.2025.05.004_bib0069","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.ard.2025.05.004_bib0070","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0071","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0072","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/rheumatology\/kead092","article-title":"A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Bentley","year":"2023","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0073","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"issue":"10452","key":"10.1016\/j.ard.2025.05.004_bib0074","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0076","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.05.004_bib0077","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","article-title":"LBA0010 Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sj\u00f6gren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS) [abstract]","volume":"83","author":"Gottenberg","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0078","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133907","article-title":"Which and how many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sj\u00f6gren's syndrome?","volume":"10","author":"Devauchelle-Pensec","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0080","first-page":"544","article-title":"Eligibility for clinical trials in primary Sj\u00f6gren\u2019s syndrome: lessons from the UK Primary Sj\u00f6gren\u2019s Syndrome Registry","volume":"55","author":"Oni","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0081","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0082","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multidimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0083","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOCQUER trial: stratification of primary Sj\u00f6gren\u2019s syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.05.004_bib0084","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard-2023-224503","article-title":"Examining the biological pathways underlying clinical heterogeneity in Sj\u00f6gren\u2019s syndrome: proteomic and network analysis","volume":"83","author":"Berry","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/art.42238","article-title":"Symptom-based cluster analysis categorizes Sj\u00f6gren's disease subtypes: an international cohort study highlighting disease severity and treatment discordance","volume":"74","author":"McCoy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0086","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-021-03051-6","article-title":"Longitudinal analysis of symptom-based clustering in patients with primary Sj\u00f6gren\u2019s syndrome: a prospective cohort study with a 5-year follow-up period","volume":"19","author":"Lee","year":"2021","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0087","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.05.004_bib0088","first-page":"2634","article-title":"Transcriptomic stratification predicts response to rituximab, abatacept or the association of hydroxychloroquine and leflunomide in 3 randomized controlled clinical trials in Sj\u00f6gren\u2019s disease [abstract]","volume":"76","author":"Chevet","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0089","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0090","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/imm.13740","article-title":"Impact of sex differences on the clinical presentation, pathogenesis, treatment and prognosis of Sj\u00f6gren\u2019s syndrome","volume":"171","author":"Xuan","year":"2024","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0091","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0092","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0093","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0094","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome\u2013a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0096","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"suppl 10","key":"10.1016\/j.ard.2025.05.004_bib0097","first-page":"2417","article-title":"A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sj\u00f6gren\u2019s syndrome [abstract]","volume":"71","author":"Mariette","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.ard.2025.05.004_bib0098","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/annrheumdis-2018-eular.3111","article-title":"OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"77","author":"D\u00f6rner","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0099","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren's syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","article-title":"Current and future therapies for primary Sj\u00f6gren syndrome","volume":"17","author":"Seror","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2025.05.004_bib0102","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-024-07165-2","article-title":"Metabolic impact of low dose IL-2 therapy for primary Sj\u00f6gren\u2019s syndrome in a double-blind, randomized clinical trial","volume":"43","author":"Feng","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0103","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004753","article-title":"Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sj\u00f6gren's disease","volume":"11","author":"de Wolff","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.05.004_bib0104","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0105","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","article-title":"Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0106","doi-asserted-by":"crossref","first-page":"100","DOI":"10.55563\/clinexprheumatol\/i8g5nd","article-title":"Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sj\u00f6gren's syndrome","volume":"133","author":"de Wolff","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0107","first-page":"1259","article-title":"Rostron J; UK Sj\u00f6gren's Interest Group. Validation of the Sicca Symptoms Inventory for clinical studies of Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Bowman","year":"2003","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0108","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1093\/rheumatology\/kead441","article-title":"Minimal added value of separate dryness assessments compared with overall dryness in ESSPRI in patients with Sj\u00f6gren\u2019s disease","volume":"63","author":"de Wolff","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.004_bib0109","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002721","article-title":"Development and testing of an alternative responder definition for EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI)","volume":"9","author":"Wratten","year":"2023","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0110","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40744-022-00489-y","article-title":"Content validity of Sj\u00f6gren\u2019s syndrome symptom diary and functional assessment of chronic illness therapy-fatigue in patients with Sj\u00f6gren\u2019s","volume":"9","author":"Griffiths","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0111","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004526","article-title":"Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sj\u00f6gren\u2019s disease","volume":"10","author":"Georgel","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0112","first-page":"12","article-title":"The Xerostomia Inventory: a multi-item approach to measuring dry mouth","volume":"16","author":"Thomson","year":"1999","journal-title":"Community Dent Health"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/03009740310000373","article-title":"The assessment of fatigue in primary Sj\u00f6gren\u2019s syndrome","volume":"32","author":"Lwin","year":"2003","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0115","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3899\/jrheum.210633","article-title":"PROMIS provides a broader overview of health-related quality of life than the ESSPRI in evaluation of Sj\u00f6gren\u2019s syndrome","volume":"49","author":"DiRenzo","year":"2022","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0116","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/acr.24144","article-title":"Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to patient-reported outcomes measurement information system fatigue scores in two phase III baricitinib rheumatoid arthritis trials","volume":"73","author":"Bingham","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.ard.2025.05.004_bib0117","first-page":"1896","article-title":"Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients","volume":"31","author":"Wolfe","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.703079","article-title":"Understanding fatigue in Sj\u00f6gren\u2019s syndrome: outcome measures, biomarkers and possible interventions","volume":"12","author":"M\u00e6land","year":"2021","journal-title":"Front Immunol"},{"issue":"5 suppl","key":"10.1016\/j.ard.2025.05.004_bib0119","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.14219\/jada.archive.2008.0353","article-title":"Measuring salivary flow: challenges and opportunities","volume":"139","author":"Navazesh","year":"2008","journal-title":"J Am Dent Assoc"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","article-title":"A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren\u2019s Syndrome International Registry","volume":"149","author":"Whitcher","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0121","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/rheumatology\/keu037","article-title":"Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sj\u00f6gren\u2019s syndrome","volume":"53","author":"Cornec","year":"2014","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0122","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/annrheumdis-2019-215024","article-title":"Video clip assessment of a salivary gland ultrasound scoring system in Sj\u00f6gren\u2019s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise","volume":"78","author":"Jousse-Joulin","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/joim.12992","article-title":"Weight of salivary gland ultrasonography compared to other items of the 2016 ACR\/EULAR classification criteria for primary Sj\u00f6gren\u2019s syndrome","volume":"287","author":"Jousse-Joulin","year":"2020","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0124","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40744-024-00645-6","article-title":"Reliability exercise of ultrasound salivary glands in Sj\u00f6gren's disease: an international web training initiative","volume":"11","author":"Qu\u00e9r\u00e9","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0125","first-page":"1229","article-title":"Salivary gland ultrasonography in the evaluation of primary Sj\u00f6gren\u2019s syndrome. Comparison with minor salivary gland biopsy","volume":"27","author":"Salaffi","year":"2000","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0126","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3899\/jrheum.200482","article-title":"Clinical phenotyping of primary Sj\u00f6gren syndrome patients using salivary gland ultrasonography: data from the RESULT cohort","volume":"48","author":"Mossel","year":"2021","journal-title":"J Rheumatol"},{"issue":"16","key":"10.1016\/j.ard.2025.05.004_bib0127","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/diagnostics13162695","article-title":"Ultra-high-frequency ultrasonography of labial glands in pediatric Sj\u00f6gren\u2019s disease: a preliminary study","volume":"13","author":"Marrani","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"17","key":"10.1016\/j.ard.2025.05.004_bib0128","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3390\/diagnostics13172771","article-title":"UHFUS: a valuable tool in evaluating exocrine gland abnormalities in Sj\u00f6gren\u2019s disease","volume":"13","author":"Fulvio","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejrad.2007.02.003","article-title":"Ultrasonographic changes of major salivary glands in primary Sj\u00f6gren\u2019s syndrome. Evaluation of a novel scoring system","volume":"63","author":"Hocevar","year":"2007","journal-title":"Eur J Radiol"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0130","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/rheumatology\/keab876","article-title":"Development of a new ultrasound scoring system to evaluate glandular inflammation in Sj\u00f6gren's syndrome: an OMERACT reliability exercise","volume":"61","author":"Ho\u010devar","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.004_bib0131","article-title":"Are ultrasound salivary parenchymal lesions more severe in primary Sj\u00f6gren patients with a longer disease duration? A cross-sectional study","author":"Tison","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0132","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ard.2025.05.004_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren\u2019s syndrome: the open-label extension phase of the ASAP-III trial","volume":"53","author":"de Wolff","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0134","first-page":"228","article-title":"Ianalumab (VAY736) in primary Sj\u00f6gren's syndrome: assessing disease activity using multi-modal ultrasound","volume":"126","author":"Diekhoff","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0135","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1136\/annrheumdis-2019-216122","article-title":"Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sj\u00f6gren\u2019s syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sj\u00f6gren\u2019s syndrome?","volume":"80","author":"Coiffier","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0136","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1136\/annrheumdis-2019-216327","volume":"80","author":"Jousse-Joulin","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0137","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/acr.24203","article-title":"Ultrasound-guided biopsy of suspected salivary gland lymphoma in Sj\u00f6gren\u2019s syndrome","volume":"73","author":"Baer","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0138","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1093\/rheumatology\/kez079","article-title":"Salivary gland ultrasonography in primary Sj\u00f6gren's syndrome: opportunities and challenges","volume":"60","author":"Devauchelle-Pensec","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.05.004_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2020.104154","article-title":"Deep learning segmentation of primary Sj\u00f6gren\u2019s syndrome affected salivary glands from ultrasonography images","volume":"129","author":"Vukicevic","year":"2021","journal-title":"Comput Biol Med"},{"issue":"12","key":"10.1016\/j.ard.2025.05.004_bib0140","first-page":"2360","article-title":"Artificial neural network and deep learning in Sj\u00f6gren's disease: where we are and where we are going","volume":"41","author":"Baldini","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.05.004_bib0141","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1093\/rheumatology\/kead071","article-title":"FDG-PET\/CT discriminates between patients with and without lymphomas in primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"van Ginkel","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0142","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.40829","article-title":"Usefulness of 18F-labeled fluorodeoxyglucose-positron emission tomography for the diagnosis of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"71","author":"Keraen","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0143","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3899\/jrheum.2023-0202","article-title":"The novel OMERACT ultrasound scoring system for salivary gland changes in patients with Sj\u00f6gren syndrome is associated with MRI and salivary flow rates","volume":"51","author":"Inanc","year":"2024","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0144","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.004_bib0145","unstructured":"ANIfrolumab treatment for 24 weeks in patients with primary Sj\u00f6gren*s syndrome - Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial (ANISE-II). WHO International Clinical Trials Registry Platform ID: NL-OMON51816. Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02719517\/full."},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.05.004_bib0146","first-page":"1455","article-title":"AB0520. Treatment of primary Sj\u00f6gren\u2019s syndrome by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod [abstract]","volume":"82","author":"Peene","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.05.004_bib0147","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2022-eular.1336","article-title":"POS0193 Evaluation of CRESS in the phase 2 randomised placebo-controlled study of sequential belimumab\/rituximab administration in patients with primary Sj\u00f6gren\u2019s syndrome [abstract]","volume":"81","author":"Bootsma","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.05.004_bib0148","unstructured":"US Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims [Internet]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"key":"10.1016\/j.ard.2025.05.004_bib0149","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaut.2015.11.002","article-title":"Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Cornec","year":"2016","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0150","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell\u2013dependent B cell hyperactivity by abatacept treatment in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0151","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3899\/jrheum.160313","article-title":"B cell depletion therapy normalizes circulating follicular Th cells in primary Sj\u00f6gren syndrome","volume":"44","author":"Verstappen","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0152","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706737","article-title":"NKp30 receptor upregulation in salivary glands of Sj\u00f6gren\u2019s syndrome characterizes ectopic lymphoid structures and is restricted by rituximab treatment","volume":"12","author":"Pontarini","year":"2021","journal-title":"Front Immunol"},{"issue":"195","key":"10.1016\/j.ard.2025.05.004_bib0153","doi-asserted-by":"crossref","first-page":"195ra96","DOI":"10.1126\/scitranslmed.3005727","article-title":"NCR3\/NKp30 contributes to pathogenesis in primary Sj\u00f6gren\u2019s syndrome","volume":"5","author":"Rusakiewicz","year":"2013","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0154","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/art.22658","article-title":"Sj\u00f6gren\u2019s Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sj\u00f6gren\u2019s syndrome, derived from an analysis of a cohort of Italian patients","volume":"56","author":"Vitali","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0155","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/rheumatology\/ken164","article-title":"The Sj\u00f6gren\u2019s Syndrome Damage Index\u2013a damage index for use in clinical trials and observational studies in primary Sj\u00f6gren\u2019s syndrome","volume":"47","author":"Barry","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.05.004_bib0156","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/rheumatology\/keq086","article-title":"Assessment of patients with primary Sj\u00f6gren\u2019s syndrome\u2013outcome over 10 years using the Sj\u00f6gren\u2019s Syndrome Damage Index","volume":"49","author":"Krylova","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0157","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/ijms25063259","article-title":"B-cell activation biomarkers in salivary glands are related to lymphomagenesis in primary Sj\u00f6gren\u2019s disease: a pilot monocentric exploratory study","volume":"25","author":"Bruno","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0158","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sj\u00f6gren\u2019s syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.05.004_bib0159","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","article-title":"Health-related quality of life, employment and disability in patients with Sj\u00f6gren\u2019s syndrome","volume":"48","author":"Meijer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.05.004_bib0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/keu361","article-title":"Do the EULAR Sj\u00f6gren\u2019s syndrome outcome measures correlate with health status in primary Sj\u00f6gren\u2019s syndrome?","volume":"54","author":"Lendrem","year":"2015","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0161","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10067-022-06119-w","article-title":"A comprehensive overview of living with Sj\u00f6gren\u2019s: results of a National Sj\u00f6gren\u2019s Foundation survey","volume":"41","author":"McCoy","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0162","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-7-46","article-title":"Primary Sj\u00f6gren\u2019s syndrome: health experiences and predictors of health quality among patients in the United States","volume":"7","author":"Segal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ard.2025.05.004_bib0163","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000443","article-title":"Patient burden of Sj\u00f6gren\u2019s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity","volume":"3","author":"Hammitt","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0164","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/kel155","article-title":"Direct healthcare costs and predictors of costs in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"46","author":"Callaghan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.05.004_bib0165","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3899\/jrheum.090734","article-title":"Estimating indirect costs in primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Bowman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0166","first-page":"98","article-title":"Sj\u00f6gren\u2019s syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options","volume":"35","author":"Birt","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0167","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3899\/jrheum.161469","article-title":"Sj\u00f6gren syndrome and work disability","volume":"44","author":"Dumusc","year":"2017","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0168","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36469\/9807","article-title":"Clinical and cost burden of primary Sj\u00f6gren\u2019s syndrome: a descriptive analysis from a US administrative claims database","volume":"5","author":"Perera","year":"2018","journal-title":"J Health Econ Outcomes Res"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0169","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40744-021-00314-y","article-title":"Primary Sj\u00f6gren\u2019s syndrome: a retrospective cohort study of burden of illness in Sweden","volume":"8","author":"Westerlund","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jval.2018.05.008","article-title":"Cost-utility analysis using EQ-5D-5L data: does how the utilities are derived matter?","volume":"22","author":"Yang","year":"2019","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.ard.2025.05.004_bib0171","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2165\/00019053-200119110-00004","article-title":"Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996)","volume":"19","author":"George","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ard.2025.05.004_bib0172","series-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","author":"Lee","year":"2017"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0173","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based single index measure for health from the SF-36","volume":"21","author":"Deverill","year":"2002","journal-title":"J Health Econ"},{"issue":"2","key":"10.1016\/j.ard.2025.05.004_bib0174","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.ard.2025.05.004_bib0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semarthrit.2017.11.007","article-title":"Assessing health-related quality of life in primary Sj\u00f6gren\u2019s syndrome-the PSS-QoL","volume":"48","author":"Lackner","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0176","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s40744-024-00718-6","article-title":"The development and content validation of the Sj\u00f6gren\u2019s Related Quality of Life Instrument (SRQoL)","volume":"11","author":"Marvel","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"10","key":"10.1016\/j.ard.2025.05.004_bib0177","doi-asserted-by":"crossref","first-page":"e2759","DOI":"10.1097\/MD.0000000000002759","article-title":"Measuring resource utilization: a systematic review of validated self-reported questionnaires","volume":"95","author":"Leggett","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2025.05.004_bib0178","series-title":"Measuring Mental Health Needs","first-page":"200","article-title":"Costing psychiatric interventions","author":"Beecham","year":"2001"},{"key":"10.1016\/j.ard.2025.05.004_bib0179","series-title":"An annotated cost questionnaire for patients [Internet]","author":"Wordsworth","year":"2001"},{"key":"10.1016\/j.ard.2025.05.004_bib0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.05.004_bib0181","first-page":"1428","article-title":"A post-hoc analysis of two phase 2 randomized controlled trials in patients with active Sj\u00f6gren\u2019s Disease exploring the novel composite endpoint Sj\u00f6gren\u2019s Tool for Assessing Response (STAR) [abstract]","volume":"76","author":"Hueber","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0182","series-title":"ICH-E9(R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials [Internet]","year":"2020"},{"issue":"7","key":"10.1016\/j.ard.2025.05.004_bib0183","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/annrheumdis-2016-210448","article-title":"Standardisation of labial salivary gland histopathology in clinical trials in primary Sj\u00f6gren\u2019s syndrome","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0184","doi-asserted-by":"crossref","first-page":"14","DOI":"10.55563\/clinexprheumatol\/8vip9k","article-title":"Sj\u00f6gren\u2019s: the European patients\u2019 community perspective","volume":"133","author":"Vieira","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0185","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40744-023-00531-7","article-title":"Patient experience of Sj\u00f6gren\u2019s disease and its multifaceted impact on patients\u2019 lives","volume":"10","author":"Perella","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.05.004_bib0186","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s43856-022-00156-x","article-title":"Patient involvement in clinical trials","volume":"2","author":"Gei\u00dfler","year":"2022","journal-title":"Commun Med (Lond)"},{"issue":"10","key":"10.1016\/j.ard.2025.05.004_bib0187","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s10067-017-3745-z","article-title":"A systematic review of primary Sj\u00f6gren\u2019s syndrome in male and paediatric populations","volume":"36","author":"Virdee","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.05.004_bib0188","doi-asserted-by":"crossref","first-page":"85","DOI":"10.55563\/clinexprheumatol\/vxe6h0","article-title":"Differences in presentation between paediatric- and adult-onset primary Sj\u00f6gren's syndrome patients","volume":"133","author":"Legger","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.05.004_bib0189","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004201","article-title":"More severe parotid gland histopathology in paediatric-onset than in adult-onset Sj\u00f6gren\u2019s disease","volume":"10","author":"Legger","year":"2024","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.ard.2025.05.004_bib0190","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sj\u00f6gren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"10.1016\/j.ard.2025.05.004_bib0191","first-page":"2225","article-title":"Selection of study endpoints and patients for clinical trials in primary Sj\u00f6gren's syndrome","volume":"40","author":"Arends","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.05.004_bib0192","article-title":"Management of Sj\u00f6gren\u2019s syndrome: present issues and future perspectives","volume":"8","author":"Vitali","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725009628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725009628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:07:44Z","timestamp":1778040464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725009628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":192,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0003496725009628"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.004","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Sj\u00f6gren\u2019s Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sj\u00f6gren\u2019s Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}